341 related articles for article (PubMed ID: 34729105)
1. uPAR: An Essential Factor for Tumor Development.
Lv T; Zhao Y; Jiang X; Yuan H; Wang H; Cui X; Xu J; Zhao J; Wang J
J Cancer; 2021; 12(23):7026-7040. PubMed ID: 34729105
[TBL] [Abstract][Full Text] [Related]
2. Role of urokinase receptor in tumor progression and development.
Noh H; Hong S; Huang S
Theranostics; 2013; 3(7):487-95. PubMed ID: 23843896
[TBL] [Abstract][Full Text] [Related]
3. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo.
Reuning U; Sperl S; Kopitz C; Kessler H; Krüger A; Schmitt M; Magdolen V
Curr Pharm Des; 2003; 9(19):1529-43. PubMed ID: 12871066
[TBL] [Abstract][Full Text] [Related]
4. The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis.
Mazar AP; Henkin J; Goldfarb RH
Angiogenesis; 1999; 3(1):15-32. PubMed ID: 14517441
[TBL] [Abstract][Full Text] [Related]
5. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
[TBL] [Abstract][Full Text] [Related]
6. The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.
Jo M; Takimoto S; Montel V; Gonias SL
Am J Pathol; 2009 Jul; 175(1):190-200. PubMed ID: 19497996
[TBL] [Abstract][Full Text] [Related]
7. The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer.
Mazar AP
Anticancer Drugs; 2001 Jun; 12(5):387-400. PubMed ID: 11395568
[TBL] [Abstract][Full Text] [Related]
8. Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model.
Zhang J; Sud S; Mizutani K; Gyetko MR; Pienta KJ
Neoplasia; 2011 Jan; 13(1):23-30. PubMed ID: 21245937
[TBL] [Abstract][Full Text] [Related]
9. uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.
Pavón MA; Arroyo-Solera I; Céspedes MV; Casanova I; León X; Mangues R
Oncotarget; 2016 Aug; 7(35):57351-57366. PubMed ID: 27385000
[TBL] [Abstract][Full Text] [Related]
10. Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy.
Mazar AP
Clin Cancer Res; 2008 Sep; 14(18):5649-55. PubMed ID: 18794071
[TBL] [Abstract][Full Text] [Related]
11. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
12. Biological significance of the expression of urokinase-type plasminogen activator receptors (uPARs) in brain tumors.
Mohanam S; Gladson CL; Rao CN; Rao JS
Front Biosci; 1999 Feb; 4():D178-87. PubMed ID: 9989951
[TBL] [Abstract][Full Text] [Related]
13. Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.
Yang JL; Seetoo Dq; Wang Y; Ranson M; Berney CR; Ham JM; Russell PJ; Crowe PJ
Int J Cancer; 2000 Sep; 89(5):431-9. PubMed ID: 11008205
[TBL] [Abstract][Full Text] [Related]
14. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
[TBL] [Abstract][Full Text] [Related]
15. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
Plesner T; Behrendt N; Ploug M
Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
[TBL] [Abstract][Full Text] [Related]
16. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor.
Ploug M; Ellis V; Danø K
Biochemistry; 1994 Aug; 33(30):8991-7. PubMed ID: 8043585
[TBL] [Abstract][Full Text] [Related]
17. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.
Magnussen SN; Hadler-Olsen E; Costea DE; Berg E; Jacobsen CC; Mortensen B; Salo T; Martinez-Zubiaurre I; Winberg JO; Uhlin-Hansen L; Svineng G
BMC Cancer; 2017 May; 17(1):350. PubMed ID: 28526008
[TBL] [Abstract][Full Text] [Related]
18. [The urokinase-type plasminogen activator system and its role in tumor progression].
Kugaevskaya EV; Gureeva TA; Timoshenko OS; Solovyeva NI
Biomed Khim; 2018 Nov; 64(6):472-486. PubMed ID: 30632975
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
20. HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer.
Indira Chandran V; Eppenberger-Castori S; Venkatesh T; Vine KL; Ranson M
Oncoscience; 2015; 2(3):207-24. PubMed ID: 25897424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
